KB120
  |  Home  |  Allergies  |  ADHD  |  Alzheimers Disease  |  Anxiety Disorders  |  Arthritis  |  Asthma  |  Back Pain  |  Breast Cancer  |  Colorectal Cancer  |  
 kb120 > Breast Cancer > Breast Cancer Topics > Breast Cancer Topic > Text
Font Size
A
A
A

Breast Cancer - References

Citations

  1. Beral V; Million Women Study Collaborators (2003). Breast Cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382): 419-427.

  2. National Cancer Institute (2006). Probability of Breast Cancer in American women. National Cancer Institute Fact Sheet. Available online: http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer.

  3. Tamimi RM, et al (2006). Combined estrogen and testosterone use and risk of Breast Cancer in postmenopausal women. Archives of Internal Medicine, 166(14): 1483-1489.

  4. American Cancer Society (2007). Breast Cancer Facts and Figures 2007. Atlanta: American Cancer Society. Available online: http://www.cancer.org/docroot/STT/stt_0.asp.

  5. Dallal CM, et al. (2007). Long-term recreational physical activity and risk of invasive and in situ Breast Cancer. Archives of Internal Medicine, 167(4): 408-415.

  6. Paley PJ (2001). Screening for the major malignancies affecting women: Current guidelines. American Journal of Obstetrics and Gynecology, 184(5): 1021-1030.

  7. Gradishar WJ (2004). male breast cancer. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 983-990. Philadelphia: Lippincott Williams and Wilkins.

  8. Women's Health Initiative Steering Committee (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14): 1701-1712.

  9. Armstrong K, et al. (2000). Assessing the risk of breast cancer. New England Journal of Medicine, 342(8): 564-570.

  10. Willett WC, et al. (2004). Nongenetic factors in the causation of Breast Cancer. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 223-276. Philadelphia: Lippincott Williams and Wilkins.

  11. Carey LA, et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21): 2492-2502.

  12. Thomas DB, et al. (2002). Randomized trial of breast self-examination in Shanghai: Final results. Journal of the National Cancer Institute, 94(19): 1445-1457.

  13. Mahon SM (2003). Evidence-based practice: Recommendations for the early detection of Breast Cancer. Clinical Journal of Oncology Nursing, 7(6): 693-696.

  14. Saslow D, et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57(2): 75-89. Available online: http://www.caonline.amcancersoc.org/cgi/content/full/57/2/75.

  15. Lehman CD, et al. (2007). MRI evaluation of the contralateral breast in women with recently diagnosed Breast Cancer. New England Journal of Medicine, 356(13): 1295-1303.

  16. Veronesi U, et al. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in Breast Cancer. New England Journal of Medicine, 349(6): 546-553.

  17. Mansel RE, et al. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable Breast Cancer: The ALMANAC trial. Journal of the National Cancer Institute, 98(9): 599-609.

  18. Smith RA, D'Orsi CJ (2004). Screening for breast cancer. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 103-130. Philadelphia: Lippincott Williams and Wilkins.

  19. Martelli G, et al. (2005). A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 Breast Cancer: Results after 5 years of follow-up. Annals of Surgery, 242(1): 1-6.

  20. Burstein HJ (2003). Breast Cancer: Supportive measures and follow-up care. In B Furie et al., eds., Clinical Hematology and Oncology, pp. 763-768. Philadelphia: Churchill Livingstone.

  21. Goss PE, et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage Breast Cancer. New England Journal of Medicine, 349(19): 1793-1802.

  22. Coombes RC, et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary Breast Cancer. New England Journal of Medicine, 350(11): 1081-1092.

  23. ATAC Trialists' Group (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for Breast Cancer. Lancet, 365(9453): 60-62.

  24. Thurlimann B, et al. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early Breast Cancer. New England Journal of Medicine, 353(26): 2747-2757.

  25. Boccardo F, et al. (2007). Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. Cancer, 109(6): 1060-1067.

  26. Chlebowski T, et al. (2003). Influence of estrogen plus progestin on Breast Cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA, 289(24): 3243-3253.

  27. Beral V, et al. (2002). Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with Breast Cancer and 96,973 women without disease. Lancet, 360(9328): 187-2218.

  28. Prentice RL, et al. (2006). Low-fat dietary pattern and risk of invasive Breast Cancer. JAMA, 295(6): 629-642.

  29. Taylor EF, et al. (2007). Meat consumption and risk of Breast Cancer in the U.K. women's cohort study. British Journal of Cancer, 96(7): 1139-1146.

  30. Cho E, et al. (2006). Red meat intake and risk of Breast Cancer among premenopausal women. Archives of Internal Medicine, 166(20): 2253-2259.

  31. McTiernan A, et al. (2004). Recreational physical activity and the risk of Breast Cancer in postmenopausal women. JAMA, 290(10): 1331-1336.

  32. Vogel VG, et al. (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive Breast Cancer and other disease outcomes: The NASBP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA, 295(23): 2727-2741.

  33. Abramowicz M (2006). Raloxifene (Evista) for breast cancer prevention in postmenopausal women. Medical Letter on Drugs and Therapeutics, 48(1234): 37.

  34. Morrow M, Gradishar W (2002). Breast Cancer. BMJ, 324(7334): 410-414.

  35. Isaacs C, et al. (2004). Evaluation and management of women with a strong family history. In JR Harris et al., eds., Diseases of the Breast, 3rd ed., pp. 315-345. Philadelphia: Lippincott Williams and Wilkins.

  36. Holmes MD, et al. (2005). Physical activity and survival after Breast Cancer diagnosis. JAMA, 293(20): 2479-2486.

  37. Drouin JS, et al. (2006). Random control clinical trial on the effects of aerobic exercise training on erythocyte levels during radiation treatment for Breast Cancer. Cancer, 107(10): 2490-2495.

  38. Ohira T, et al. (2006). Effect of weight training on quality of life in recent breast cancer survivors: The Weight Training for Breast Cancer Survivors (STBS) study. Cancer, 106(9): 2076-2083.

  39. Collado-Hidalgo A, et al. (2006). Inflammatory biomarkers for persistent fatigue in Breast Cancer survivors. Clinical Cancer Research, 12(9): 2759-2766.

  40. Kris MG, et al. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Journal of Clinical Oncology, 24(18): 2932-2937.

  41. National Cancer Institute (2006). Breast Cancer PDQ: Treatment-Health Professional Version. Available online: http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional.

  42. Harris EER, et al. (2006). Late cardiac mortality and morbidity in early-stage Breast Cancer patients after breast-conservation treatment. Journal of Clinical Oncology, 24(25): 4100-4106.

  43. Hooning MJ, et al. (2007). Long-term risk of cardiovascular disease in 10-year survivors of Breast Cancer. Journal of the National Cancer Institute, 99(5): 365-375.